Details

Autor(en) / Beteiligte

• Boadu, Emmanuel
• Choi, Hong Y.
• Lee, Diana W.K.
• Waddington, Emma I.
• Chan, Teddy
• Asztalos, Bela
• Vance, Jean E.
• Chan, Alicia
• Castro, Graciela
• Francis, Gordon A.

Titel

Correction of Apolipoprotein A-I-mediated Lipid Efflux and High Density Lipoprotein Particle Formation in Human Niemann-Pick Type C Disease Fibroblasts

Ist Teil von

• The Journal of biological chemistry, 2006-12, Vol.281 (48), p.37081-37090

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2006

Quelle

MEDLINE

Beschreibungen/Notizen

• Impaired cell cholesterol trafficking in Niemann-Pick type C (NPC) disease results in the first known instance of impaired regulation of the ATP-binding cassette transporter A1 (ABCA1), a lipid transporter mediating the rate-limiting step in high density lipoprotein (HDL) formation, as a cause of low plasma HDL-cholesterol in humans. We show here that treatment of human NPC1-/- fibroblasts with the liver X receptor (LXR) agonist TO-901317 increases ABCA1 expression and activity in human NPC1-/- fibroblasts, as indicated by near normalization of efflux of radiolabeled phosphatidylcholine and a marked increase in efflux of cholesterol mass to apoA-I. LXR agonist treatment prior to and during apoA-I incubation resulted in reduction in filipin staining of unesterified cholesterol in late endosomes/lysosomes, as well as cholesterol mass, in NPC1-/- cells. HDL species in human NPC disease plasma showed the same pattern of diminished large, cholesterol-rich α-1 HDL particles as seen in isolated heterozygous ABCA1 deficiency. Incubating NPC1-/- fibroblasts with the LXR agonist normalized the pattern of HDL particle formation by these cells. ABCG1, another LXR target gene involved in cholesterol efflux to HDL, also showed diminished expression in NPC1-/- fibroblasts and increased expression upon LXR agonist treatment. These results suggest that NPC1 mutations can be largely bypassed and that NPC1 protein function is non-essential for the trafficking and removal of cellular cholesterol if the down-stream defects in ABCA1 and ABCG1 regulation in NPC disease cells are corrected using an LXR agonist.